ReviewBiomedicines2017
Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies.
Review in Biomedicines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 55 citations in OpenAlex.
- Advancements in pharmaceutical research on traditional Chinese medicine-metal complexes.Journal of pharmaceutical analysis · 2026Review
- Article
- Improving Cytotoxicity of Saporin with Saponin SO1406 Isolated from the Roots of Saponaria Officinalis.Biomedicines · 2026Article
- Engineering Gypsophila elegans hairy root cultures to produce endosomal escape-enhancing saponins.Plant biotechnology journal · 2025Article
- Enhanced initiation of somatic embryos in suspension cultures ofFrontiers in plant science · 2025Article
- Article
- Mutational Analysis of RIP Type I Dianthin-30 Suggests a Role for Arg24 in Endocytosis.Toxins · 2024Article
- A cleavable peptide adapter augments the activity of targeted toxins in combination with the glycosidic endosomal escape enhancer SO1861.BMC biotechnology · 2024Article
- Enhancing health and therapeutic potential: innovations in the medicinal and pharmaceutical properties of soy bioactive compounds.Frontiers in pharmacology · 2024Review
- Saponin Fraction CIL1 fromPharmaceutics · 2023Article
- Effects of saponins from Chinese herbal medicines on signal transduction pathways in cancer: A review.Frontiers in pharmacology · 2023Review
- Enhanced cytotoxicity of aFrontiers in pharmacology · 2023Article
- Synergistic Cytotoxicity of a Toxin Targeting the Epidermal Growth Factor Receptor and the Glycosylated Triterpenoid SO1861 in Prostate Cancer.Journal of Cancer · 2023Article
- Article
- Tissue Culture Response of Ornamental and MedicinalPlants (Basel, Switzerland) · 2022Review
- Targeted Toxins for the Treatment of Prostate Cancer.Biomedicines · 2021Review
- Magnetic Nanoparticle-Based Dianthin Targeting for Controlled Drug Release Using the Endosomal Escape Enhancer SO1861.Nanomaterials (Basel, Switzerland) · 2021Article
- Physiologically Active Molecules and Functional Properties of Soybeans in Human Health-A Current Perspective.International journal of molecular sciences · 2021Review
- Article
- Elucidating Carbohydrate-Protein Interactions Using Nanoparticle-Based Approaches.Frontiers in chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein-based targeted toxins play an increasingly important role in targeted tumor therapies. In spite of their high intrinsic toxicity, their efficacy in animal models is low. A major reason for this is the limited entry of the toxin into the cytosol of the target cell, which is required to mediate the fatal effect. Target receptor bound and internalized toxins are mostly either recycled back to the cell surface or lysosomally degraded. This might explain why no antibody-targeted protein toxin has been approved for tumor therapeutic applications by the authorities to date although more than 500 targeted toxins have been developed within the last decades. To overcome the problem of insufficient endosomal escape, a number of strategies that make use of diverse chemicals, cell-penetrating or fusogenic peptides, and light-induced techniques were designed to weaken the membrane integrity of endosomes. This review focuses on glycosylated triterpenoids as endosomal escape enhancers and throws light on their structure, the mechanism of action, and on their efficacy in cell culture and animal models. Obstacles, challenges, opportunities, and future prospects are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.